Zatolmilast is a Small Molecule owned by Tetra Therapeutics, and is involved in 11 clinical trials, of which 7 were completed, and 4 are ongoing.

BPN-14770 elicit therapeutic intervention by acting as inhibitor to phosphodiesterase 4 (PDE 4D). Phosphodiesterase 4D is the subtype of enzyme PDE4 which breaks down cAMP, an important neuronal and intracellular signaling molecule. The drug candidate by blocking PDE4 activity activates the protein kinase A which phosphorylates and activates the subsequent downstream target cAMP-response element binding (CREB) protein. This signalling cascade by enhancing the memory improves cognitive functions and disease condition.

The revenue for Zatolmilast is expected to reach a total of $496m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zatolmilast NPV Report.

Zatolmilast is originated and owned by Tetra Therapeutics. Shionogi & is the other company associated in development or marketing of Zatolmilast.

Zatolmilast Overview

BPN-14770 is under development for the treatment of fragile X syndrome, traumatic brain injury and Alzheimer's disease. The drug candidate is administered through oral route. It acts by targeting enzyme phosphodiesterase 4 (PDE 4D) enzyme.

Shionogi & Overview

Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.

Quick View – Zatolmilast

Report Segments
  • Innovator
Drug Name
  • Zatolmilast
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.